Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in key scientific and investor conferences in April 2021. Notably, at the 2021 Virtual AAN Annual Meeting, Robert J. Fox, M.D., will present data from the phase 2 EMPhASIS trial of IMU-838 for relapsing-remitting multiple sclerosis. The B. Riley Neuroscience Conference will also feature Dr. Daniel Vitt discussing Immunic's developments. Furthermore, Dr. Vitt will present on IMU-838's application in COVID-19 at the German Corona Showcase 2021. Access to presentation materials will be available on Immunic's website.
On March 31, 2021, Immunic (Nasdaq: IMUX) announced an agreement with 4SC AG to settle a 4.4% royalty on net sales of their lead program, IMU-838, for $17.25 million. Payment will be made 50% in cash and 50% in stock. This acquisition eliminates remaining payment obligations and allows Immunic to capture 100% of future sales from IMU-838, which targets conditions like multiple sclerosis and ulcerative colitis. The company plans to initiate a phase 3 trial later in 2021, furthering its potential market growth.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on immunology therapies, announced its participation in several industry and investor conferences in March 2021. Key events include the 2nd Annual European HealthTech CEO Forum on March 8-9, where CEO Daniel Vitt will discuss IMU-838's potential for COVID-19. Other conferences include the H.C. Wainwright Global Life Sciences Conference, BioCapital Europe 2021, and the 33rd Annual Roth Conference. Participants can view presentations on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) reported its financial results for the year ending December 31, 2020, highlighting significant clinical milestones. The company demonstrated clinical activity of its lead asset, IMU-838, in COVID-19 patients and reported positive outcomes in a phase 2 trial for primary sclerosing cholangitis. R&D expenses rose to $38.6 million, while G&A expenses decreased to $10.3 million. The net loss was approximately $44 million. Immunic ended 2020 with $127.5 million in cash, projected to fund operations into mid-2022.
Immunic, Inc. (Nasdaq: IMUX) announced promising data from a phase 2 proof-of-concept trial for IMU-838, targeting primary sclerosing cholangitis (PSC). Out of 18 enrolled patients, 11 completed the treatment. Statistically significant reductions in serum alkaline phosphatase (ALP) were noted, with 27.3% of evaluable patients achieving a >25% reduction. The drug demonstrated safety with rare mild adverse events. Although limited by COVID-19 challenges, the results suggest further development for IMU-838 in treating PSC is warranted, with potential for additional trials.
Immunic, Inc. (Nasdaq: IMUX) reported positive results from its phase 2 CALVID-1 trial evaluating IMU-838, a selective oral DHODH inhibitor, for hospitalized COVID-19 patients. The analysis included data from 204 patients, demonstrating low rates of invasive ventilation (1%) and mortality (<2%). IMU-838 showed clinical activity, with a higher proportion of patients recovering by day 28 (71.3% vs. 66.7% placebo). The drug was found to be safe and well-tolerated, with notable benefits for high-risk and elderly populations. A full analysis of all 223 patients is expected in Q2 2021.
Immunic, Inc. (Nasdaq: IMUX) announced CEO Daniel Vitt will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 10:00 am ET. A live audio webcast will be accessible on Immunic's website, with an archived version available for 90 days post-conference. Immunic focuses on developing selective oral therapies for chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis. Its lead program, IMU-838, has shown positive results in clinical trials.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in two major investor conferences in January: the H.C. Wainwright BioConnect 2021 Conference and the 39th Annual J.P. Morgan Healthcare Conference. CEO Daniel Vitt will present at the Wainwright event starting January 11, while Glenn Whaley, Vice President Finance, will attend the J.P. Morgan event. Additionally, Immunic updated its phase 2 clinical trial for IMU-838 to treat primary sclerosing cholangitis, with results expected in Q1 2021 due to COVID-19 delays.
Immunic, Inc. (Nasdaq: IMUX) has announced its selection for the NASDAQ Biotechnology Index, effective December 21, 2020. This index tracks biotechnology and pharmaceutical firms on NASDAQ, based on specific performance criteria. Immunic is focused on developing oral immunology therapies for chronic inflammatory and autoimmune diseases, with promising results from its phase 2 EMPhASIS trial of lead product IMU-838, targeting multiple sclerosis. The company also has ongoing trials for ulcerative colitis, Crohn's disease, and COVID-19, showcasing its commitment to advancing treatments in this sector.
Immunic, Inc. (Nasdaq: IMUX) announced participation in investor conferences from November 30 to December 3, 2020. Key events include the Piper Sandler 32nd Virtual Healthcare Conference, where CEO Daniel Vitt will engage in a fireside chat, and the Evercore ISI 3rd Annual HEALTHCONx Conference with a presentation on December 3. Archived replays will be available on Immunic's website. The company develops selective oral therapies for chronic inflammatory diseases, with promising results for its lead product, IMU-838.